Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Toripalimab in Advanced HCC
NCT03919383Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: 6 months progression free survival rates. Planned start Apr 2019; status: withdrawn.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03919383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919383.